Male reproductive organ cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- A primary or metastatic malignant neoplasm involving the male reproductive system. Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Male reproductive organ cancer
- Therapeutic area
- Oncology
- male reproductive organ cancer
- cancer of male reproductive organ
- Male Genital Cancer
- malignant male reproductive organ neoplasm
- malignant Male reproductive system neoplasm
- malignant Male reproductive system tumor
- malignant Male reproductive system tumour
- malignant neoplasm of male genital organ, site unspecified
- malignant neoplasm of male reproductive organ
- malignant neoplasm of Male reproductive system
- malignant neoplasm of the Male reproductive system
- malignant tumor of male genital organ
- malignant tumor of Male reproductive system
- malignant tumor of the Male reproductive system
- malignant tumour of male genital organ
- malignant tumour of Male reproductive system
- malignant tumour of the Male reproductive system
- Recurrent Malignant Male Reproductive System Neoplasm
- Refractory Malignant Male Reproductive System Neoplasm
- male genital neoplasm
- male reproductive system neoplasm
- neoplasm of male genital organ
- tumor of male reproductive system
- tumour of male reproductive system
- Severity
- Severe
- Oncology
- Reproductive Health
Sources for recorded values
- MONDO ID
- MONDO:0005836
- Parent condition
- MONDO:0002149
Related records
Broader conditions (13)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Male reproductive system disorder
- Male reproductive system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
Narrower conditions (113)
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Adenosquamous prostate carcinoma
- Basaloid carcinoma of the penis
- Carcinoma of Cowper glands
- Castration-resistant prostate carcinoma
- Childhood embryonal testis carcinoma
- Childhood testicular choriocarcinoma
- Childhood testicular mixed embryonal carcinoma and teratoma
- Childhood testicular mixed germ cell cancer
- Choriocarcinoma of testis
- Cribriform variant testicular seminoma
- Enteric pattern testicular yolk sac tumor
- Epididymal adenocarcinoma
- Epididymis cancer
- Familial prostate carcinoma
- Glans penis cancer
- Grade III prostatic intraepithelial neoplasia
- Hormone-resistant prostate carcinoma
Trials (40)
- [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
- 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
- A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
- A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer
- A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
- A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
- A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
- CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
- Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.
- Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer
- Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
- Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle
- EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
- Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
- Health Gatherings - For Your Health After Cancer
- High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
- Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
Drugs in development (9)
- Clonidine Phase 3
- Daratumumab Phase 2
- Dexamethasone Phase 3
- Docetaxel Phase 3
- Epinephrine Phase 3
- Fospropofol Phase 3
- Propofol Phase 3
- Ropivacaine Phase 3
- ST. JOHN'S WORT Phase 3